Technically...this isn't a breakout yet.
Trimesta News is what will make this break out for good.
For tech players as I said -- many place certain criteria on their charting software screeners which is good because it familiarizes newbies with SYN and they will study this and decide whether to take profits, hold or accumulate for the longer term which is bullish. Everything was Converging and it had to make a minimum .10 cent adjustment to diverge a little bit.
If we get the C. Diff news tomorrow that could run us close 1.95.
What it does from there? No clue. Depends on how positive the data is perceived.
What should keep the shorts at bay? Trimesta --- they could be completely dried, crusty, burned TOAST, so they will play with their penny's and should keep the big shorts away as there are much, much, much better stocks to make easy money on shorting and when you have news that could instantly Quadruple a stock, that is one that the may think twice about taking a position.
If no news for the rest of the week...well, I think we've been through this routine a hundred times now.
You're Lucky...99% of those idiots....... they rob from you, but you are probably one that is robbing!
I wish I knew how to do this. Been trading for 16 years and haven't had the guts or I should say confidence/know how to do this.
But that sounds like pretty dang good. You win either way.
Can you explain "if I have the stock called away".
I believe I am a very good trader but I do it by reading charts and research and to add options in would be another weapon.
I agree. This is Severely Undervalued though. They probably are sitting on the best in class drug for MS ever. A lot of positives to come...I am anxious to hear about the FDA meeting.
Phase III Clinical Trials Protocol meeting with FDA AFTER Dr. Voskhul's presentation of MRI results. I don't care if the information is the same as we have heard....I have been Waiting for them to say "We have to schedule a meeting with the FDA about these results and discuss the necessary Protocol for an Acceptable Phase III trial"
So this is now confirmed and that will be very interesting.
They are in over a $17 Billion global market, even if only approved for U.S. that is plenty.
4 new provisional patents filed based on the positive finding last year.
SYN-004 over a $10 Billion market. They should be close to Phase III ready by EOY. Plus in earlier studies with an earlier version of the enzyme it PREVENTED Resistance in Ampiciillin administered vial IV. Look if MD's wouldn't have to worry about Resistance forming they would likely use Ampicillin. This could be really Great news for those suffering with Respiratory Diseases and infections.
Top Line Data from Second Generation called SYN-004 in first Quarter. Then immediately to follow is Phase II-a, and second part of year Phase II-b.
Syn-010 --- treating IBS-C which could go for the root cause instead of treating symptoms. This one will be VERY interesting. They discovered by removing methane will reverse constipation and improve symptoms of the discomforts that go with it. This drug is non-systemic which means a LOT less money in testing and doesn't interrupt microbial activity...which means it can be used Long Term. 505(b)2 FDA approval pathway which Expedites the approval process and cuts costs significantly.
Expect IND by JUNE 2015 and they can directly Jump to Phase II this year and be in Phase III next year.
This company is undervalued.
SYN-005 Whooping Cough --- Riley says he is looking for "outside" funding options --- probably from WHO or some other organization which aids in treating outside U.S diseases.
A lot to look forward to!!!
IF this could stay in this range for a couple more weeks, I think this will be a Major play. I agree with you...I think this will leave this range sooner.
The deeper I dig the worse it gets about Kriegsman and the FDA. What a corrupt field...meaning the STS cancer sub types.
No positive projected income until late 2019 or 2020 and that is assuming everything goes right.
A great drug would produce stat sig on a 100 patient study...this drug is not great, in fact it is not much better than doing nothing at all and if one would #$%$ a special cancer diet with nutriceuticals they would live longer.
PFS and OS are not to be correlated...that is plain to see. They are just ignoring the sub types of sarcoma? This HAS to change, even though there is little money in STS for big boys like Novartis --- it is a NVS that could make the difference.
Ziop could even develop biomarkers and re-do their studies and pass with flying colors, but evidently they don't believe that sub-type would be enough market and plus you would have to do test to convince the FDA that the biomarkers are pertinent.
By the way...No profitability until late 2019 or 2020 is the estimate. That is over 4 years from now and hopefully by then there will be biomarkers to make a better diagnosis of what type of STS a cancer patient has.
You would think that Novartis would do some trials by then as they have a very powerful drug that could really work on a certain population of STS.
It's just plain dumb or stupid that Kriegsman is treating all patients with chemo when a good portion will not respond. All cancers are different and will respond differently to different medicines.
I do feel bad for these STS patients as they drug makers are not focusing on the many forms of soft tissue sarcomas...they need to label them and make orphan status for each subtype. That is my opinion and what I believe is the right thing to do.
From Cytrx S-8: If we obtain marketing approval and successfully commercialize aldoxorubicin or other product candidate, we anticipate it will take a minimum of several years, and likely longer, for us to generate significant recurring revenue.
Plus: STS will NEVER be treated correctly until they divide the Sarcomas into categories which are chemo-Sensitive and Chemo-Insensitive and there are other drugs that could greatly help these patients if they do this.
If CYTR did this they would succeed with a landslide but they are intentionally treating knowing that some patients will not be Effected one single bit by Chemotherapy of any kind...they would need drugs such as Gleevec or some of the other KIT inhibitors and it wouldn't take much to find out which are these patients...but that would be a lot of work...plus there are plenty of KIT inhibitors....so the Dirty Minded Kriegsman makes a deal with the devil (FDA) about increasing the population to over 400 and hoping there will be enough patients who respond to Aldoxo...which there should at that enrollment level, but the patients here have NO Clue that 1/3 of them will receive no benefit whatsoever. It's all in the name of GREED because it would cost a lot of money to do it right and thus take away 1/3 of the "untreatable" population that Kriegsman will get to treat by doing it this way.
With so few treatments available the FDA supposedly has agreed to the primary of PFS, which is a CROCK...will it Really help? It may help a little and we will find out Next year. Kriegsman says 2017 approval...that's if everything goes exactly as planned....How often does this occur in clinical trials.
For SCLC --- there are a lot of new drugs being developed and some of them will likely be approved which really will effect profits if that is every approved in 2019 or 2020. So realistically, even if Aldox is approved for both conditions the market is shrinking quickly. The max of a Billion MC by 2020 after further analysis
They always do this to try and start a run...do ya think it will work?
I always check the after hour phony trades and it is ridiculous, if someone wanting in they can EASILY get in.
I'm sure the FDA will approve it also. But if you are rooting for Cancer, this is a #$%$ JOKE. Yeah, the stock will go up at some point in time, but as far as treating cancer, it's no better than Doxo--- a little safer in the right patients, but one mess up and next time the halt may be longer.
Dose to progression...this is Fuzzy Math as G Bush would say.
PFS was TWICE as much as Doxo, so one would assume that OS would at the VERY LEAST be DOUBLE, not 1.6 months better. Results were so disappointing that they didn't even come Close to stat sig. They will have to do a study with 4 times the patients to even think about Stat Sig and that is NOT GOOD, been a pharmaceutical investor for 16 years and know when I see good data. This really wasn't good, you build expectations when you see a PFS that is Double the PFS of doxorubicin.
This says there is NO Correlation...big word in statistics, no Correlation between the PFS data.
Maybe the bashers will disappear and cover to raise the price.
The next study they are putting the primary as PFS and secondary as OS.
I can see the corrupt FDA agreeing to this, but the OS is what doctors will look at period. There is no guarantee that Aldox will beat out a treatment of choice.
I was blown away to hear that it was only 1.6 months...when all the indications from the LYING management informed me that the delay was due to "possible people living longer", Yeah, living longer in the Dox treatment...freaking deceiving spinners.
To even say such a thing when they OBVIOUSLY knew this a LONG time ago. You DON"T put out Good News on a Thursday....NEVER.
They also Omitted the 1.6 months from the press release....that is flat our Trickery.
Has anyone EVER seen a PR from Kriegsman that didn't "SOUND" extremely positive...and then you read it and it's like "nothing has been PROVEN yet and they are saying this is a shoe in approval"
It is likely that Aldo is very Slightly better than Doxo....Slightly....will the FDA approve it....they probably will. Will it be a Block buster? NO...even if they had 100% of the World themselves it wouldn't be a blockbuster.